Experimental ALS injection shows early promise in slowing decline
NCT ID NCT04632225
Summary
This small study tested whether injections of an experimental drug called Engensis are safe for people with ALS (Lou Gehrig's disease). Eighteen participants received either the drug or a placebo injection into their muscles over several months. Researchers primarily checked for side effects, but also looked for early signs that the treatment might help slow the loss of muscle strength and function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Neuromuscular Center
Austin, Texas, 78759, United States
-
Hanyang University Medical Center
Seoul, 04763, South Korea
-
Johns Hopkins University Department of Neurology
Baltimore, Maryland, 21205, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
St. Joseph's Hospital and Medical Center, Barrows Neurological Institute
Phoenix, Arizona, 85013, United States
Conditions
Explore the condition pages connected to this study.